Drs. Thomas Patterson, Chief, Division of Infectious Diseases, and Jason Bowling, Infectious Diseases, explained the implications of the FDA fast-tracking emergency authorization of the new anti-viral drug, remdesivir, as the new standard of care for hospitalized COVID-19 patients.

Read and watch the full story.

The post KSAT 12: San Antonio doctor involved in remdesivir trial says FDA emergency approval is ‘very exciting’ appeared first on UT Health San Antonio.